tislelizumab + chemotherapy

Tislelizumab + chemotherapy is a combination therapy that has shown significant efficacy in treating various cancers, particularly gastric, gastroesophageal junction, and esophageal cancers. This combination leverages the immunotherapeutic properties of tislelizumab with the cytotoxic effects of chemotherapy. ## Description Tislelizumab is a humanized IgG4 monoclonal antibody that targets programmed death receptor-1 (PD-1). It has been engineered with a nullified Fc portion to minimize binding to FcγR on macrophages, which helps limit treatment resistance via antibody-dependent phagocytosis[6][10]. By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through enhanced cytokine production, resulting in immune-mediated antitumor responses[6][10]. When combined with chemotherapy, this treatment approach has demonstrated significant clinical benefits in multiple cancer types. The combination has received FDA approval for specific indications, including first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinomas with PD-L1 expression[5][8][9]. Clinical trials, such as RATIONALE-305 and RATIONALE-306, have shown that tislelizumab plus chemotherapy significantly improves overall survival compared to chemotherapy alone in various cancer types[5][7]. For example, in the RATIONALE-306 trial for esophageal squamous cell carcinoma, the combination showed a median overall survival of 16.8 months versus 9.6 months with chemotherapy alone[7]. The safety profile of tislelizumab in combination with chemotherapy has been reported as consistent with the known risks of each component, with manageable and generally mild-to-moderate adverse effects[4][6].

Brand names

Tevimbra + chemotherapy